Peter Blume Jensen
About Peter Blume Jensen
Peter Blume-Jensen - CEO, President, Founder, Chairperson
Peter Blume-Jensen serves as the CEO, President, Founder, and Chairperson. With extensive experience in precision oncology R&D and in-licensing leadership, Peter has built a notable career. His role encompasses strategic decision-making and guiding the organization's overall direction. He utilizes his vast expertise to drive innovation and growth within the company.
Peter Blume-Jensen's Education and Expertise
Peter Blume-Jensen holds an M.D. from Copenhagen University Medical School in Denmark and a Ph.D. from The Ludwig Institute for Cancer Research in Uppsala, Sweden. He also completed a Post-Doctoral Fellowship under Tony Hunter at the Salk Institute in La Jolla, CA. Peter has three decades of experience in oncogenic kinase signaling, phosphoproteomics, and clinical drug and biomarker development, contributing significantly to the field of precision oncology.
Peter Blume-Jensen's Professional Background in the Pharmaceutical Industry
Peter Blume-Jensen has held executive positions at notable companies such as Serono, Merck & Co., and Daiichi Sankyo. Furthermore, he served as the Chief Scientific Officer at Metamark Genetics and played a pivotal role in developing the first marketed prostate test, ProMark®. His professional background showcases a strong commitment to advancing cancer treatment and diagnostics.
Peter Blume-Jensen's Contributions to Precision Oncology
Peter Blume-Jensen is the inventor of the AP3 platform and the OncoSignature patient selection method, critical tools in precision oncology. His contributions are well-recognized in the field, evidenced by his highly cited review on Oncogenic Kinase Signaling published in Nature (2001). Through his work, Peter continues to influence cancer research and treatment strategies.
Peter Blume-Jensen's Role in Advisory Boards
Peter Blume-Jensen serves on the Scientific Advisory Board for several private biotech companies and academic institutions. His expertise in oncology and drug development makes him a valuable advisor, contributing to scientific advancements and strategic directions in the biotechnology and academic fields.